AMENDMENT NO. 1 TO CREDIT AGREEMENTCredit Agreement • April 20th, 2017 • Pernix Therapeutics Holdings, Inc. • Pharmaceutical preparations • New York
THIS AMENDMENT NO. 1 TO CREDIT AGREEMENT (this "Amendment") is made and entered into as of April 18, 2017, by and among PERNIX THERAPEUTICS HOLDINGS, INC., a Maryland corporation ("Parent"), PERNIX THERAPEUTICS, LLC, a Louisiana limited liability company ("Therapeutics"), PERNIX SLEEP, INC., a Delaware corporation ("Sleep"), CYPRESS PHARMACEUTICALS, INC., a Mississippi corporation ("Cypress"), GAINE, INC., a Delaware corporation ("Gaine"), RESPICOPEA INC., a Delaware corporation ("Respicopea"), MACOVEN PHARMACEUTICALS, L.L.C., a Louisiana limited liability company ("Macoven"), HAWTHORN PHARMACEUTICALS, INC., a Mississippi corporation ("Hawthorn"; together with Parent, Therapeutics, Sleep, Cypress, Gaine, Respicopea and Macoven, are referred to hereinafter each individually as a "Borrower", and individually and collectively, jointly and severally, as the "Borrowers"), the lenders under the Credit Agreement (as hereinafter defined) party hereto (the "Lenders") and WELLS FARGO BANK, NATIO
